TSPO and schizophrenia: There is evidence for higher levels of markers associated with an activated glial phenotype in schizophrenia relative to controls from post-mortem studies (effect size ~0.7 on meta-analysis) [166], and that greater PET signal for TSPO, a protein expressed by activated glia, is associated with greater predicted complement levels in patients [84].